BridgeBio has significantly boosted this course of a novel therapy for ATTR-CM, leveraging the investigational drug. Initial trial results reveals potential outcomes for patients diagnosed by a serious illness. The https://biotech692223.blog5.net/95104357/firm-advances-attr-cm-treatment-using-the-therapy